385 related articles for article (PubMed ID: 20581246)
1. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.
Rössle M; Gerbes AL
Gut; 2010 Jul; 59(7):988-1000. PubMed ID: 20581246
[TBL] [Abstract][Full Text] [Related]
2. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
3. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
Senzolo M; Cholongitas E; Tibballs J; Burroughs A; Patch D
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1143-50. PubMed ID: 17033432
[TBL] [Abstract][Full Text] [Related]
4. Transjugular intrahepatic portosystemic shunt--role in treating intractable variceal bleeding, ascites, and hepatic hydrothorax.
LaBerge JM
Clin Liver Dis; 2006 Aug; 10(3):583-98, ix. PubMed ID: 17162229
[TBL] [Abstract][Full Text] [Related]
5. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
[TBL] [Abstract][Full Text] [Related]
6. The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension.
Hassoun Z; Pomier-Layrargues G
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):1-4. PubMed ID: 15095845
[TBL] [Abstract][Full Text] [Related]
7. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
[TBL] [Abstract][Full Text] [Related]
8. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
9. Transjugular intrahepatic portosystemic shunts: an update.
Rosado B; Kamath PS
Liver Transpl; 2003 Mar; 9(3):207-17. PubMed ID: 12619016
[TBL] [Abstract][Full Text] [Related]
10. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality.
Russo MW; Sood A; Jacobson IM; Brown RS
Am J Gastroenterol; 2003 Nov; 98(11):2521-7. PubMed ID: 14638358
[TBL] [Abstract][Full Text] [Related]
11. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
Colombato L
J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
[TBL] [Abstract][Full Text] [Related]
12. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.
Bai M; Qi XS; Yang ZP; Yang M; Fan DM; Han GH
World J Gastroenterol; 2014 Mar; 20(10):2704-14. PubMed ID: 24627607
[TBL] [Abstract][Full Text] [Related]
13. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
Salerno F; Guevara M; Bernardi M; Moreau R; Wong F; Angeli P; Garcia-Tsao G; Lee SS
Liver Int; 2010 Aug; 30(7):937-47. PubMed ID: 20492521
[TBL] [Abstract][Full Text] [Related]
14. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites.
Garcia-Tsao G
Nat Clin Pract Gastroenterol Hepatol; 2006 Jul; 3(7):380-9. PubMed ID: 16819501
[TBL] [Abstract][Full Text] [Related]
15. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.
Salerno F; Cammà C; Enea M; Rössle M; Wong F
Gastroenterology; 2007 Sep; 133(3):825-34. PubMed ID: 17678653
[TBL] [Abstract][Full Text] [Related]
16. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
Narahara Y; Kanazawa H; Fukuda T; Matsushita Y; Harimoto H; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Nakatsuka K; Sakamoto C
J Gastroenterol; 2011 Jan; 46(1):78-85. PubMed ID: 20632194
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.
Albillos A; Bañares R; González M; Catalina MV; Molinero LM
J Hepatol; 2005 Dec; 43(6):990-6. PubMed ID: 16139922
[TBL] [Abstract][Full Text] [Related]
18. Transjugular intrahepatic portosystemic shunt.
Ochs A
Dig Dis; 2005; 23(1):56-64. PubMed ID: 15920326
[TBL] [Abstract][Full Text] [Related]
19. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
Guevara M; Ginès P; Bandi JC; Gilabert R; Sort P; Jiménez W; Garcia-Pagan JC; Bosch J; Arroyo V; Rodés J
Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
[TBL] [Abstract][Full Text] [Related]
20. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
